ABSTRACT
During the resent years there has been interest in using bone marrow stem cells to treat liver cirrhosis. However, there is a potential concern for malignant transformation after stem cell therapy. The aim of this study was to evaluate the development of hepatocellular carcinoma [HCC] after autologous bone marrow stem cell transplantation for liver cirrhosis. All the patients who underwent autologous stem cell transplantation for liver cirrhosis between 2005 and 2011 at our center were enrolled. Cellular infusion was made through peripheral vein, portal vein, or hepatic artery.The patients were invited to undergo screening for hepatocellular carcinoma. The screening was made with ultrasonography and alpha-feto protein [AFP] measurement. Thirty two patients [18 males] were included in the study. Mean age of patients was 45.7 years. Fifteen patients [47%] received mesenchymal stem cell [MSC], 9 [28%] received bone marrow mononuclear cells, 5 [16%] were given CD 133-positive bone marrow cells, and 3 [9%] patients received CD 34-positive bone marrow cells. Mean duration of follow up was 20.5months. Mean serum level of AFP was 2.8 ng/ml at baseline and 3.4ng/ml at the end of follow up [p= 0.3]. One patient was found to have hepatocellular carcinoma three months after infusion of bone marrow mononuclear cells. The incidence rate for HCC was 1.8 cases per 100 person-years in this study. Autologous bone marrow stem cell infusion does not appear to increase the risk of hepatocellular carcinoma. The incidence rate of HCC in this study is comparable or even less than the reported rates of HCC in cohort studies of cirrhotic patients
ABSTRACT
A functional treatment for skeletal damages in orthopedic and oral maxillofacial surgeries is required. Platelet growth factors such as Platelet Derived Growth Factor [PDGF], Bone Morphogenic Factor [BMP], Transferring Growth Factor-beta [TGF-beta] and Insulin-like Growth Factor-1 [IGF-1] precede wound healing and bone regeneration. In the present study we focused on the effect of platelet rich plasma [PRP], platelet rich plasma gel [PRP-Gel] and auto bone chips on this process. 30 male, 22 weeks old, Sprague-Dawley rats weighing 525 g were used. They were divided in three groups consisting of PRP [treated by Platelet-Rich Plasma], PRP-Gel [treated by it], Bone chips and Control [two cavities created in each animal in this group]. After 16 weeks they were histologically investigated while in the periods of 40, 60, 90and 120 days, the radiography had been done. The radiographic analysis showed complete treatment in all groups; however, by the histo-pathological investigations by auto bone chips complete and PRP-Gel partial healing has been observed. By histo-morphometric surveys [100+/-25] % in bone chips and [50+/-25] % in PRP-Gel groups bone bridging were observed, whereas in PRP it was not noticeable. The Present study suggests that neither PRP, nor PRP-Gel could be as beneficial as bone chips. Statistically, in PRP-Gel group, due to the existence of fibrin and thrombin, solid bone bridging at the treated site is indicated. According to the previous studies, in which the key role of both inhibitory and stimulatory signals in controlling the bone regeneration were proven, we suggest that auto bone chips could completely enhance healing due to signals among blood factors, environmental tissues and skeletal particles
ABSTRACT
The field of stem cell biology and regenerative medicine is rapidly moving toward translation to clinical practice. Stem cell therapy seems to be a new treatment option for some diseases. So, tracking the distribution of stem cells is crucial to their therapeutic use. Based on this fact we labeled human mesenchymal stem cells [MSCs] with 111In-oxine for the first time in our country. The aim of this study was to investigate the possibility of stem cell labeling in Iran. In addition the researchers assessed the cell viability, specific activity and labeling efficiency after labeling. After culturing mesenchymal stem cells [MSCs], for radio-labeling, the sample [which contained 1x106MSCs] were mixed, and suspended with 50 micro Ci 111In-oxine, and then incubated for 20 min at the room temperature. The cells were then washed with normal saline twice to remove the free 111In. The labeling efficiency, specific activity and cell viability was 70.6%, 31.70 micro Ci/106 and 100%, respectively. It seems that, this method is practical and easily applicable with acceptable efficiency and specific activity in our laboratory settings using pharmaceutical produced in Iran